OBJECTIVE: To describe the course of patients with juvenile dermatomyositis (JDM) treated effectively without systemic corticosteroids. STUDY DESIGN: A retrospective study of 38 patients with JDM treated at a tertiary care children's hospital identified 8 patients who had never received corticosteroids. Disease presentation and course, pharmacologic, and ancillary treatments were recorded. RESULTS: Patients in the no corticosteroid group were followed for a median of 2.8 years (range, 2.1 to 9.5 years). Treatment was primarily with intravenous immunoglobulin (IVIG) (75%) and methotrexate (50%), with favorable response in all. No serious treatment complications were observed; headaches were reported by 3 patients receiving IVIG. Two patients had a myositis flare after discontinuing all medications for more than 1 year; complete resolution of symptoms was observed after either 1 or 2 further doses of IVIG. Two patients had calcinosis (at 1 and 9 years of disease); however, no patient had joint contractures, muscle atrophy, lipodystrophy, or functional limitations. CONCLUSIONS: Systemic corticosteroids can be avoided in a select group of patients with JDM. Alternative agents such as methotrexate and IVIG may be prescribed to effectively treat JDM and prevent complications. Copyright 2010 Mosby, Inc. All rights reserved.
OBJECTIVE: To describe the course of patients with juvenile dermatomyositis (JDM) treated effectively without systemic corticosteroids. STUDY DESIGN: A retrospective study of 38 patients with JDM treated at a tertiary care children's hospital identified 8 patients who had never received corticosteroids. Disease presentation and course, pharmacologic, and ancillary treatments were recorded. RESULTS:Patients in the no corticosteroid group were followed for a median of 2.8 years (range, 2.1 to 9.5 years). Treatment was primarily with intravenous immunoglobulin (IVIG) (75%) and methotrexate (50%), with favorable response in all. No serious treatment complications were observed; headaches were reported by 3 patients receiving IVIG. Two patients had a myositis flare after discontinuing all medications for more than 1 year; complete resolution of symptoms was observed after either 1 or 2 further doses of IVIG. Two patients had calcinosis (at 1 and 9 years of disease); however, no patient had joint contractures, muscle atrophy, lipodystrophy, or functional limitations. CONCLUSIONS: Systemic corticosteroids can be avoided in a select group of patients with JDM. Alternative agents such as methotrexate and IVIG may be prescribed to effectively treat JDM and prevent complications. Copyright 2010 Mosby, Inc. All rights reserved.
Authors: J Heckmatt; N Hasson; C Saunders; N Thompson; A M Peters; G Cambridge; M Rose; S A Hyde; V Dubowitz Journal: Lancet Date: 1989-05-13 Impact factor: 79.321
Authors: M C Dalakas; I Illa; J M Dambrosia; S A Soueidan; D P Stein; C Otero; S T Dinsmore; S McCrosky Journal: N Engl J Med Date: 1993-12-30 Impact factor: 91.245
Authors: Amir B Orandi; Lampros Fotis; Jamie Lai; Hallie Morris; Andrew J White; Anthony R French; Kevin W Baszis Journal: Pediatr Rheumatol Online J Date: 2021-08-17 Impact factor: 3.054
Authors: Amir B Orandi; Vikas R Dharnidharka; Noor Al-Hammadi; Kevin W Baszis Journal: Pediatr Rheumatol Online J Date: 2018-12-29 Impact factor: 3.054